Last reviewed · How we verify
Antihyperglycemic Drug — Competitive Intelligence Brief
marketed
Diabetes
Small molecule
Live · refreshed every 30 min
Target snapshot
Antihyperglycemic Drug (Antihyperglycemic Drug) — Sanofi. Antihyperglycemic drugs lower blood glucose levels through various mechanisms such as enhancing insulin secretion, improving insulin sensitivity, or reducing hepatic glucose production.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Antihyperglycemic Drug TARGET | Antihyperglycemic Drug | Sanofi | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Antihyperglycemic Drug CI watch — RSS
- Antihyperglycemic Drug CI watch — Atom
- Antihyperglycemic Drug CI watch — JSON
- Antihyperglycemic Drug alone — RSS
Cite this brief
Drug Landscape (2026). Antihyperglycemic Drug — Competitive Intelligence Brief. https://druglandscape.com/ci/antihyperglycemic-drug. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab